Skip to main content
For US Healthcare Professionals Only
Quick Links
Prescribing information
BIMZELX® (bimekizumab-bkzx)
BRIVIACT® (brivaracetam) CV
CIMZIA® (certolizumab pegol)
FINTEPLA® (fenfluramine)
KYGEVVI® (doxecitine and doxribtimine)
NAYZILAM® (midazolam) CIV
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
REMS
FINTEPLA® (fenfluramine)
ZILBRYSQ® (zilucoplan)
Adverse Event Reporting
Report an Adverse Event or Product Complaint
Email
1-844-599-CARE (2273)
Connect With an MSL
Connect With Us
Main navigation
Home
Our Science
Overview
Clinical Pipeline
Opportunities for Investigators
Scientific Education
Overview
Dermatology
Epilepsy
Rare Disease
Rheumatology
Podcasts
Independent Medical Education
Congress Materials
Publications
Medical Information
Overview
Submit Medical Inquiry
HCP Resources
Overview
Search HCP Resources
Slide Library
Prescribing Information
Connect With an MSL
Connect With Us
BIMZELX® (bimekizumab-bkzx)
BRIVIACT® (brivaracetam) CV
CIMZIA® (certolizumab pegol)
FINTEPLA® (fenfluramine)
KYGEVVI® (doxecitine and doxribtimine)
NAYZILAM® (midazolam) CIV
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
REMS
FINTEPLA® (fenfluramine)
ZILBRYSQ® (zilucoplan)
Home
Congress Materials
European Academy of Neurology (EAN), 2026
Congress Materials
European Academy of Neurology (EAN), 2026
Filter
Close
Filter
Search
Keyword (eg, author, condition)
Content type:
Interactive Poster
Medical Symposium
Oral Presentation
Poster
Video
Tab
Apply filters
Clear filters
Efficacy of long-term rozanolixizumab treatment cycles in patients with generalised myasthenia gravis: A subgroup analysis of Phase 3 studies
Sabrina Sacconi, Giovanni Antonini, Elena Cortés Vicente, et al.
Poster
Efficacy of long-term zilucoplan treatment in subgroups of patients with generalised myasthenia gravis: A 120-week analysis of RAISE-XT
M. Isabel Leite, Miriam Freimer, Channa Hewamadduma, et al.
Poster